Emergent Biosolutions
(EBS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -186,200 | -211,600 | -144,600 | -60,100 | -3,700 |
| Depreciation Amortization | 35,600 | 154,100 | 110,700 | 77,400 | 31,900 |
| Income taxes - deferred | -4,700 | -28,600 | 25,500 | 2,600 | 1,900 |
| Accounts receivable | 2,600 | 118,100 | 82,500 | 97,700 | 93,700 |
| Accounts payable and accrued liabilities | 31,000 | -14,000 | -11,800 | -7,600 | -14,700 |
| Other Working Capital | -36,100 | -2,100 | -167,300 | -52,600 | -76,400 |
| Other Operating Activity | -26,200 | -50,000 | -21,900 | -110,300 | -70,000 |
| Operating Cash Flow | $-184,000 | $-34,100 | $-126,900 | $-52,900 | $-37,300 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -15,100 | -115,800 | -92,200 | -64,300 | -32,200 |
| Net Acquisitions | N/A | -243,700 | -243,700 | N/A | N/A |
| Purchase Sale Intangibles | N/A | -21,800 | N/A | N/A | N/A |
| Other Investing Activity | 0 | -21,800 | 0 | 0 | 0 |
| Investing Cash Flow | $-15,100 | $-381,300 | $-335,900 | $-64,300 | $-32,200 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 0 | 598,000 | 238,000 | -16,900 | -8,500 |
| Debt Repayment | -8,400 | -33,800 | -25,300 | N/A | N/A |
| Common Stock Repurchased | N/A | -82,100 | -81,900 | -81,900 | -57,500 |
| Other Financing Activity | -2,100 | -900 | -2,700 | -2,400 | -4,500 |
| Financing Cash Flow | $-10,500 | $481,200 | $128,100 | $-101,200 | $-70,500 |
| Exchange Rate Effect | -200 | 500 | -600 | 400 | -300 |
| Beginning Cash Position | 642,600 | 576,300 | 576,300 | 576,300 | 576,300 |
| End Cash Position | 430,200 | 642,600 | 241,000 | 358,300 | 436,000 |
| Net Cash Flow | $-212,400 | $66,300 | $-335,300 | $-218,000 | $-140,300 |
| Free Cash Flow | |||||
| Operating Cash Flow | -184,000 | -34,100 | -126,900 | -52,900 | -37,300 |
| Capital Expenditure | -15,100 | -115,800 | -92,200 | -64,300 | -32,200 |
| Free Cash Flow | -199,100 | -149,900 | -219,100 | -117,200 | -69,500 |